List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7504769/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA - Journal of the American Medical Association, 2009, 302, 2323.	7.4	2,682
2	Mortality after surgery in Europe: a 7 day cohort study. Lancet, The, 2012, 380, 1059-1065.	13.7	1,614
3	Epidemiology and Outcomes of Ventilator-Associated Pneumonia in a Large US Database. Chest, 2002, 122, 2115-2121.	0.8	1,089
4	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current Â-Lactam Antibiotic Doses Sufficient for Critically III Patients?. Clinical Infectious Diseases, 2014, 58, 1072-1083.	5.8	843
5	Pneumonia in intubated patients: role of respiratory airway care American Journal of Respiratory and Critical Care Medicine, 1996, 154, 111-115.	5.6	727
6	Linezolid vs Vancomycin *. Chest, 2003, 124, 1789-1797.	0.8	590
7	A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically III Patients. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 56-64.	5.6	497
8	Continuous Aspiration of Subglottic Secretions in Preventing Ventilator-Associated Pneumonia. Annals of Internal Medicine, 1995, 122, 179.	3.9	464
9	The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 196-200.	5.6	460
10	Impact of Previous Antimicrobial Therapy on the Etiology and Outcome of Ventilator-associated Pneumonia. Chest, 1993, 104, 1230-1235.	0.8	459
11	An International Prospective Study of Pneumococcal Bacteremia: Correlation with In Vitro Resistance, Antibiotics Administered, and Clinical Outcome. Clinical Infectious Diseases, 2003, 37, 230-237.	5.8	426
12	Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes American Journal of Respiratory and Critical Care Medicine, 1994, 150, 1545-1549.	5.6	421
13	Combination Antibiotic Therapy Lowers Mortality among Severely Ill Patients with Pneumococcal Bacteremia. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 440-444.	5.6	421
14	Community-Acquired Bloodstream Infection in Critically Ill Adult Patients. Chest, 2003, 123, 1615-1624.	0.8	420
15	Variations in Etiology of Ventilator-associated Pneumonia across Four Treatment Sites. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 608-613.	5.6	404
16	Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Critical Care, 2009, 13, R148.	5.8	399
17	Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Critical Care Medicine, 2002, 30, 521-528.	0.9	383
18	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically III Patients. Clinical Pharmacokinetics, 2011, 50, 99-110.	3.5	325

#	Article	IF	CITATIONS
19	Evaluation of Outcome of Intravenous Catheter-related Infections in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 1027-1030.	5.6	324
20	Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Medicine, 2012, 38, 1930-1945.	8.2	322
21	Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Critical Care, 2009, 13, R201.	5.8	316
22	Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Critical Care, 2015, 19, 7.	5.8	310
23	Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Medicine, 2004, 30, 388-394.	8.2	301
24	Incidence, Etiology, and Outcome of Nosocomial Pneumonia in Mechanically Ventilated Patients. Chest, 1991, 100, 439-444.	0.8	298
25	Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy*. Critical Care Medicine, 2007, 35, 1888-1895.	0.9	288
26	Sepsis: A Review of Advances in Management. Advances in Therapy, 2017, 34, 2393-2411.	2.9	276
27	De-escalation therapy in ventilator-associated pneumonia*. Critical Care Medicine, 2004, 32, 2183-2190.	0.9	237
28	Use of high-flow nasal cannula oxygenation in ICU adults: a narrative review. Intensive Care Medicine, 2016, 42, 1336-1349.	8.2	237
29	Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Medicine, 2010, 36, 612-620.	8.2	235
30	Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1999-2006.	2.9	230
31	Why Do Physicians Not Follow Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia?. Chest, 2002, 122, 656-661.	0.8	221
32	Antibiotic Prescription for Community-Acquired Pneumonia in the Intensive Care Unit: Impact of Adherence to Infectious Diseases Society of America Guidelines on Survival. Clinical Infectious Diseases, 2005, 41, 1709-1716.	5.8	220
33	Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni. Chest, 2003, 124, 91S.	0.8	218
34	International Conference for the Development of Consensus on the Diagnosis and Treatment of Ventilator-Associated Pneumonia. Chest, 2001, 120, 955-970.	0.8	217
35	Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock*. Critical Care Medicine, 2007, 35, 1493-1498.	0.9	210
36	A Worldwide Perspective of Atypical Pathogens in Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1086-1093.	5.6	209

#	Article	IF	CITATIONS
37	A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Medicine, 2014, 40, 839-845.	8.2	209
38	An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Critical Care, 2015, 19, 219.	5.8	209
39	Survival in patients with nosocomial pneumonia. Critical Care Medicine, 1997, 25, 1862-1867.	0.9	206
40	Severity of Pneumococcal Pneumonia Associated With Genomic Bacterial Load. Chest, 2009, 136, 832-840.	0.8	202
41	A European care bundle for prevention of ventilator-associated pneumonia. Intensive Care Medicine, 2010, 36, 773-780.	8.2	196
42	PIRO score for community-acquired pneumonia: A new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia*. Critical Care Medicine, 2009, 37, 456-462.	0.9	194
43	Secretion of the Toxin ExoU Is a Marker for Highly VirulentPseudomonas aeruginosalsolates Obtained from Patients with Hospitalâ€Acquired Pneumonia. Journal of Infectious Diseases, 2003, 188, 1695-1706.	4.0	193
44	Severe Community-Acquired Pneumonia in the Elderly: Epidemiology and Prognosis. Clinical Infectious Diseases, 1996, 23, 723-728.	5.8	192
45	Nosocomial Respiratory Tract Infections in Multiple Trauma Patients. Chest, 1992, 102, 525-529.	0.8	188
46	Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Critical Care Medicine, 2009, 37, 2360-2369.	0.9	188
47	Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenzaÂA infection. Intensive Care Medicine, 2011, 37, 272-283.	8.2	188
48	Risk Factors for Developing Pneumonia within 48 Hours of Intubation. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1742-1746.	5.6	187
49	SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 553-561.	1.4	186
50	Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis*. Critical Care Medicine, 2003, 31, 367-373.	0.9	185
51	Antibiotic use in patients with COVID-19: a â€~snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey. Journal of Antimicrobial Chemotherapy, 2020, 75, 3386-3390.	3.0	185
52	Late Admission to the ICU in Patients With Community-Acquired Pneumonia Is Associated With Higher Mortality. Chest, 2010, 137, 552-557.	0.8	179
53	Microbiological Testing and Outcome of Patients With Severe Community-Acquired Pneumonia. Chest, 2003, 123, 174-180.	0.8	176
54	Epidemiology, Species Distribution, Antifungal Susceptibility, and Outcome of Candidemia across Five Sites in Italy and Spain. Journal of Clinical Microbiology, 2013, 51, 4167-4172.	3.9	176

#	Article	IF	CITATIONS
55	Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study. Intensive Care Medicine, 2017, 43, 1808-1819.	8.2	176
56	Pseudomonas aeruginosa virulence and therapy: Evolving translational strategies*. Critical Care Medicine, 2009, 37, 1777-1786.	0.9	172
57	Evaluation of Outcome for Intubated Patients with Pneumonia Due to Pseudomonas aeruginosa. Clinical Infectious Diseases, 1996, 23, 973-978.	5.8	171
58	Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides*. Critical Care Medicine, 2005, 33, 1983-1987.	0.9	169
59	Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. European Respiratory Journal, 2006, 27, 1210-1216.	6.7	169
60	Pneumonia in the intensive care unit. Critical Care Medicine, 2003, 31, 2544-2551.	0.9	168
61	Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respiratory Medicine,the, 2015, 3, 53-60.	10.7	166
62	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	8.2	165
63	Community-Acquired Respiratory Coinfection in Critically Ill Patients With Pandemic 2009 Influenza A(H1N1) Virus. Chest, 2011, 139, 555-562.	0.8	164
64	Effect of High-Flow Nasal Cannula and Body Position on End-Expiratory Lung Volume: A Cohort Study Using Electrical Impedance Tomography. Respiratory Care, 2013, 58, 589-596.	1.6	162
65	A Three-year Study of Severe Community-acquired Pneumonia With Emphasis on Outcome. Chest, 1993, 103, 232-235.	0.8	161
66	Therapy of ventilator-associated pneumonia. Intensive Care Medicine, 2003, 29, 876-883.	8.2	160
67	Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study*. Critical Care Medicine, 2003, 31, 2478-2482.	0.9	160
68	Global Prospective Epidemiologic and Surveillance Study of Ventilator-Associated Pneumonia due to Pseudomonas aeruginosa*. Critical Care Medicine, 2014, 42, 2178-2187.	0.9	157
69	High-flow nasal therapy in adults with severe acute respiratory infection. Journal of Critical Care, 2012, 27, 434-439.	2.2	156
70	Association of Serotypes of Streptococcus pneumoniae with Disease Severity and Outcome in Adults: An International Study. Clinical Infectious Diseases, 2007, 45, 46-51.	5.8	153
71	Nursing adherence with evidence-based guidelines for preventing ventilator-associated pneumonia*. Critical Care Medicine, 2003, 31, 2693-2696.	0.9	152
72	Prevalence, Risk Factors, and Mortality for Ventilator-Associated Pneumonia in Middle-Aged, Old, and Very Old Critically III Patients*. Critical Care Medicine, 2014, 42, 601-609.	0.9	150

#	Article	IF	CITATIONS
73	Risk factors for infection byPseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Medicine, 1994, 20, 193-198.	8.2	148
74	The Role of Candida sp Isolated From Bronchoscopic Samples in Nonneutropenic Patients. Chest, 1998, 114, 146-149.	0.8	147
75	Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients. Intensive Care Medicine, 2014, 40, 1340-1351.	8.2	147
76	Host adaptive immunity deficiency in severe pandemic influenza. Critical Care, 2010, 14, R167.	5.8	145
77	Increased mortality associated with meticillin-resistant Staphylococcus aureus (MRSA) infection in the Intensive Care Unit: results from the EPIC II study. International Journal of Antimicrobial Agents, 2011, 38, 331-335.	2.5	145
78	Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality*. Critical Care Medicine, 2004, 32, 625-631.	0.9	144
79	Reduced burden of bacterial airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study*. Critical Care Medicine, 2006, 34, 2766-2772.	0.9	144
80	Ventilator-associated pneumonia. European Task Force on ventilator-associated pneumonia Chairmen of the Task Force: A. Torres and J. Carlet. European Respiratory Journal, 2001, 17, 1034-1045.	6.7	142
81	Risk Factors for <i>Staphylococcus aureus</i> Nosocomial Pneumonia in Critically III Patients. The American Review of Respiratory Disease, 1990, 142, 1320-1324.	2.9	139
82	Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest, 2003, 124, 1789-97.	0.8	139
83	Drugâ€Resistant Pneumococcal Pneumonia: Clinical Relevance and Related Factors. Clinical Infectious Diseases, 2004, 38, 787-798.	5.8	138
84	Centers for Disease Control and Prevention guidelines for preventing central venous catheter-related infection: Results of a knowledge test among 3405 European intensive care nurses*. Critical Care Medicine, 2009, 37, 320-323.	0.9	138
85	Nosocomial bacteremia in a medical-surgical intensive care unit: Epidemiologic characteristics and factors influencing mortality in 111 episodes. Intensive Care Medicine, 1994, 20, 94-98.	8.2	137
86	Recurrent <i>Pseudomonas aeruginosa</i> Pneumonia in Ventilated Patients. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 912-916.	5.6	137
87	Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Medicine, 2020, 46, 298-314.	8.2	135
88	Impact of diversity of antibiotic use on the development of antimicrobial resistance. Journal of Antimicrobial Chemotherapy, 2006, 57, 1197-1204.	3.0	134
89	Oral care practices in intensive care units: aÂsurvey of 59 European ICUs. Intensive Care Medicine, 2007, 33, 1066-1070.	8.2	134
90	Evidence on measures for the prevention of ventilator-associated pneumonia. European Respiratory Journal, 2007, 30, 1193-1207.	6.7	130

#	Article	IF	CITATIONS
91	New Issues and Controversies in the Prevention of Ventilator-associated Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 870-876.	5.6	130
92	Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. European Respiratory Journal, 2020, 55, 2001028.	6.7	130
93	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. Journal of Antimicrobial Chemotherapy. 2016. 71. 196-207.	3.0	129
94	Risk Factors for Infection by Acinetobacter baumannii in Intubated Patients With Nosocomial Pneumonia. Chest, 1997, 112, 1050-1054.	0.8	123
95	Interleukin-6 Is a Potential Biomarker for Severe Pandemic H1N1 Influenza A Infection. PLoS ONE, 2012, 7, e38214.	2.5	122
96	Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection, 2017, 23, 629-639.	6.0	121
97	The Ventilator-Associated Pneumonia PIRO Score. Chest, 2008, 134, 1208-1216.	0.8	120
98	Gentamicin volume of distribution in critically ill septic patients. Intensive Care Medicine, 1990, 16, 303-306.	8.2	119
99	C-reactive protein used as an early indicator of infection in patients with systemic inflammatory response syndrome. Intensive Care Medicine, 2004, 30, 2038-2045.	8.2	119
100	A care bundle approach for prevention of ventilator-associated pneumonia. Clinical Microbiology and Infection, 2013, 19, 363-369.	6.0	119
101	C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. Critical Care Medicine, 2008, 36, 166-171.	0.9	118
102	Impact of Obesity in Patients Infected With 2009 Influenza A(H1N1). Chest, 2011, 139, 382-386.	0.8	117
103	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. Clinical Infectious Diseases, 2019, 68, 1482-1493.	5.8	116
104	Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. Journal of Antimicrobial Chemotherapy, 2011, 66, 1140-1149.	3.0	114
105	Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Medicine, 2013, 39, 672-681.	8.2	114
106	A Clinical Trial on the Prevention of Catheter-Related Sepsis Using a New Hub Model. Annals of Surgery, 1996, 223, 363-369.	4.2	114
107	Impact of Antibiotic Guideline Compliance on Duration of Mechanical Ventilation in Critically III Patients With Community-Acquired Pneumonia. Chest, 2006, 130, 93-100.	0.8	112
108	Quality of Life, Pulmonary Function, and Tomographic Scan Abnormalities After ARDS. Chest, 2011, 139, 1340-1346.	0.8	112

#	Article	IF	CITATIONS
109	Legionnaires' disease: a rational approach to therapy. Journal of Antimicrobial Chemotherapy, 2003, 51, 1119-1129.	3.0	110
110	Bacteremia in patients with ventilator-associated pneumonia is associated with increased mortality: A study comparing bacteremic vs. nonbacteremic ventilator-associated pneumonia*. Critical Care Medicine, 2007, 35, 2064-2070.	0.9	109
111	Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infectious Diseases, The, 2016, 16, 1364-1376.	9.1	109
112	Clinical resolution in patients with suspicion of ventilator-associated pneumonia: A cohort study comparing patients with and without acute respiratory distress syndrome*. Critical Care Medicine, 2005, 33, 1248-1253.	0.9	108
113	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. Critical Care, 2015, 19, 33.	5.8	108
114	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. Journal of Infection, 2016, 72, 143-151.	3.3	108
115	Adult ICU Triage During the Coronavirus Disease 2019 Pandemic: Who Will Live and Who Will Die? Recommendations to Improve Survival*. Critical Care Medicine, 2020, 48, 1196-1202.	0.9	108
116	Cutaneous manifestations in COVIDâ€19: the experiences of Barcelona and Rome. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e306-e307.	2.4	108
117	Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection, 2018, 24, 1264-1272.	6.0	107
118	Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: Report of Eight Cases and Review. Clinical Infectious Diseases, 1998, 26, 1473-1475.	5.8	106
119	Improving Outcomes in Elderly Patients With Community-Acquired Pneumonia by Adhering to National Guidelines. Archives of Internal Medicine, 2009, 169, 1515.	3.8	106
120	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults. Chest, 2020, 158, 1896-1911.	0.8	105
121	Infection of Hemodialysis Catheters: Incidence and Mechanisms. American Journal of Nephrology, 1989, 9, 454-459.	3.1	104
122	Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. Critical Care, 2014, 18, R58.	5.8	104
123	Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia*. Critical Care Medicine, 2007, 35, 2509-2514.	0.9	103
124	Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeSâ€, a multinational observational cohort study and ESICM Trials Group Project. Intensive Care Medicine, 2019, 45, 1703-1717.	8.2	103
125	Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among European intensive care nurses. Journal of Hospital Infection, 2008, 70, 180-185.	2.9	102
126	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. Journal of Antimicrobial Chemotherapy, 2010, 65, 1771-1778.	3.0	102

#	Article	IF	CITATIONS
127	Benefits of minocycline and rifampin-impregnated central venous catheters. Intensive Care Medicine, 2004, 30, 1891-1899.	8.2	100
128	Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Advances in Therapy, 2020, 37, 1302-1318.	2.9	100
129	Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. Cmaj, 2010, 182, 357-363.	2.0	99
130	A Randomized Trial of Dental Brushing for Preventing Ventilator-Associated Pneumonia. Chest, 2009, 136, 433-439.	0.8	98
131	EFFECTS OF HIGH-DOSE OF INTRAVENOUS IMMUNOGLOBULIN AND ANTIBIOTICS ON SURVIVAL FOR SEVERE SEPSIS UNDERGOING SURGERY. Shock, 2005, 23, 298-304.	2.1	97
132	A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 319-323.	2.9	97
133	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Medicine, 2020. 46. 245-265.	8.2	97
134	Innovative continuous non-invasive cuffless blood pressure monitoring based on photoplethysmography technology. Intensive Care Medicine, 2013, 39, 1618-1625.	8.2	96
135	Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy. Journal of Critical Care, 2013, 28, 741-746.	2.2	95
136	Advances in antibiotic therapy in the critically ill. Critical Care, 2016, 20, 133.	5.8	94
137	Incidence, Etiology, and Outcome of Nosocomial Pneumonia in ICU Patients Requiring Percutaneous Tracheotomy for Mechanical Ventilation. Chest, 2003, 124, 2239-2243.	0.8	93
138	Management of Community-acquired Pneumonia in Adults. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 157-164.	5.6	92
139	Pseudomonas aeruginosa ventilator-associated pneumonia management. Infection and Drug Resistance, 2016, 9, 7.	2.7	92
140	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. Current Opinion in Critical Care, 2008, 14, 390-396.	3.2	90
141	Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates using pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Medicine, 2004, 30, 1768-1775.	8.2	89
142	Clinical review: Primary influenza viral pneumonia. Critical Care, 2009, 13, 235.	5.8	88
143	Bacteremia is an independent risk factor for mortality in nosocomial pneumonia: a prospective and observational multicenter study. Critical Care, 2011, 15, R62.	5.8	87
144	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Critical Care, 2014, 18, R99.	5.8	87

#	Article	IF	CITATIONS
145	Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults. Anesthesiology, 2017, 126, 890-908.	2.5	87
146	Human Mesenchymal Stem Cells Overexpressing the IL-33 Antagonist Soluble IL-1 Receptor–Like–1 Attenuate Endotoxin-Induced Acute Lung Injury. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 552-562.	2.9	85
147	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically III Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. Clinical Infectious Diseases, 2021, 72, 1369-1378.	5.8	85
148	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review, 2020, 29, 200287.	7.1	82
149	Raising concerns about the Sepsis-3 definitions. World Journal of Emergency Surgery, 2018, 13, 6.	5.0	81
150	The Presence of Pneumococcal Bacteremia Does Not Influence Clinical Outcomes in Patients With Community-Acquired Pneumonia. Chest, 2008, 133, 618-624.	0.8	80
151	Antibiotic Dosing in Multiple Organ Dysfunction Syndrome. Chest, 2011, 139, 1210-1220.	0.8	80
152	Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive and Critical Care Nursing, 2022, 70, 103227.	2.9	80
153	Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. European Respiratory Journal, 2011, 37, 1332-1339.	6.7	78
154	Tobacco Smoking Increases the Risk for Death From Pneumococcal Pneumonia. Chest, 2014, 146, 1029-1037.	0.8	78
155	Fundamentals of aerosol therapy in critical care. Critical Care, 2016, 20, 269.	5.8	78
156	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study. Thorax, 2013, 68, 1007-1014.	5.6	77
157	A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Critical Care, 2017, 21, 22.	5.8	77
158	Initial management of pneumonia and sepsis: factors associated with improved outcome. European Respiratory Journal, 2012, 39, 156-162.	6.7	76
159	Impact of infection on the prognosis of critically ill cirrhotic patients: results from a large worldwide study. Liver International, 2014, 34, 1496-1503.	3.9	76
160	Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Medicine, 2009, 35, 430-438.	8.2	73
161	Anxiety among front-line health-care workers supporting patients with COVID-19: A global survey. General Hospital Psychiatry, 2021, 68, 90-96.	2.4	73
162	Early non-invasive ventilation treatment for severe influenza pneumonia. Clinical Microbiology and Infection, 2013, 19, 249-256.	6.0	72

#	Article	IF	CITATIONS
163	A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Medicine, 2003, 29, 1981-1988.	8.2	71
164	Decrease in Mortality in Severe Community-Acquired Pneumococcal Pneumonia. Chest, 2014, 146, 22-31.	0.8	71
165	Prevention and Diagnosis of Ventilator-Associated Pneumonia. Chest, 2005, 128, 1667-1673.	0.8	69
166	Why Mortality Is Increased in Health-Care-Associated Pneumonia. Chest, 2010, 137, 1138-1144.	0.8	68
167	Pneumonia due to Haemophilus influenzae Among Mechanically Ventilated Patients. Chest, 1992, 102, 1562-1565.	0.8	67
168	Ventilator-Associated Pneumonia. Chest, 2008, 133, 625-632.	0.8	67
169	Genomic islands ofPseudomonas aeruginosa. FEMS Microbiology Letters, 2009, 290, 70-78.	1.8	67
170	Endotracheal tube intraluminal diameter narrowing after mechanical ventilation: use of acoustic reflectometry. Intensive Care Medicine, 2004, 30, 2204-2209.	8.2	65
171	Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia. European Respiratory Journal, 2010, 36, 1073-1079.	6.7	65
172	Influence of Renal Function on the Pharmacokinetics of Piperacillin/Tazobactam in Intensive Care Unit Patients During Continuous Venovenous Hemofiltration. Journal of Clinical Pharmacology, 2005, 45, 168-176.	2.0	64
173	Bacteraemic pneumococcal pneumonia: Impact of HIV on clinical presentation and outcome. Journal of Infection, 2007, 55, 125-135.	3.3	63
174	Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infection and Drug Resistance, 2011, 4, 31.	2.7	63
175	Hybrid Pathogenicity Island PAGI-5 Contributes to the Highly Virulent Phenotype of a <i>Pseudomonas aeruginosa</i> Isolate in Mammals. Journal of Bacteriology, 2008, 190, 7130-7140.	2.2	62
176	Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clinical Microbiology and Infection, 2017, 23, 640-646.	6.0	62
177	Performance of existing definitions and tests for the diagnosis of invasive aspergillosis in critically ill, adult patients: A systematic review with qualitative evidence synthesis. Journal of Infection, 2020, 81, 131-146.	3.3	62
178	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. PLoS ONE, 2016, 11, e0145929.	2.5	61
179	Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Tigecycline. Journal of Chemotherapy, 2005, 17, 12-22.	1.5	60
180	The Spectrum of Pneumococcal Empyema in Adults in the Early 21st Century. Clinical Infectious Diseases, 2011, 53, 254-261.	5.8	60

#	Article	IF	CITATIONS
181	Validation of Predictors of Adverse Outcomes in Hospital-Acquired Pneumonia in the ICU*. Critical Care Medicine, 2013, 41, 2151-2161.	0.9	60
182	Respiratory infections in patients undergoing mechanical ventilation. Lancet Respiratory Medicine,the, 2014, 2, 764-774.	10.7	59
183	Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study. Critical Care, 2016, 20, 53.	5.8	59
184	Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation*. Critical Care Medicine, 2010, 38, 1135-1140.	0.9	58
185	Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Critical Care Medicine, 2001, 29, N82-N86.	0.9	57
186	Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Medicine, 2002, 28, 1030-1035.	8.2	57
187	Ventilator-associated pneumonia caused by ESKAPE organisms. Current Opinion in Pulmonary Medicine, 2012, 18, 187-193.	2.6	57
188	Corticosteroid therapy in patients with primary viralÂpneumonia due to pandemic (H1N1) 2009Âinfluenza. Journal of Infection, 2012, 64, 311-318.	3.3	57
189	Ventilator-associated pneumonia: issues related to the artificial airway. Respiratory Care, 2005, 50, 900-6; discussion 906-9.	1.6	57
190	Ventilator-Associated Pneumonia in Trauma Patients Is Associated With Lower Mortality: Results From EU-VAP Study. Journal of Trauma, 2010, 69, 849-854.	2.3	56
191	Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia. Chest, 2012, 142, 1193-1199.	0.8	56
192	Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock. A prospective pilot study. Medicina Intensiva, 2012, 36, 475-480.	0.7	56
193	Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality. Medicina (Lithuania), 2019, 55, 49.	2.0	56
194	Role of bronchoalveolar lavage in mechanically ventilated patients with suspected pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 1994, 13, 549-558.	2.9	55
195	Severity of illness scoring systems in patients with bacteraemic pneumococcal pneumonia: implications for the intensive care unit care. Clinical Microbiology and Infection, 2009, 15, 850-857.	6.0	55
196	Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. International Journal of Antimicrobial Agents, 2009, 33, 554.e1-554.e7.	2.5	55
197	Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia. International Journal of Tuberculosis and Lung Disease, 2011, 15, 542-546.	1.2	55
198	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. Cytokine, 2016, 88, 267-273.	3.2	54

#	Article	IF	CITATIONS
199	Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. International Journal of Antimicrobial Agents, 2010, 35, 421-430.	2.5	53
200	European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clinical Microbiology and Infection, 2014, 20, 19-36.	6.0	53
201	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the <scp>FUN</scp> gal infections Definitions in <scp>ICU</scp> patients (<scp>FUNDICU</scp>) project. Mycoses, 2019, 62, 310-319.	4.0	53
202	Serial surveillance cultures of skin and catheter hub specimens from critically ill patients with central venous catheters: molecular epidemiology of infection and implications for clinical management and research. Journal of Clinical Microbiology, 1997, 35, 1784-1790.	3.9	53
203	Effect of Antibiotic Diversity on Ventilator-Associated Pneumonia Caused by ESKAPE Organisms. Chest, 2011, 140, 643-651.	0.8	52
204	Microbial causes of ventilator-associated pneumonia. Seminars in Respiratory Infections, 1996, 11, 24-31.	1.3	52
205	Influence of genetic variability at the surfactant proteins A and D in community-acquired pneumonia: a prospective, observational, genetic study. Critical Care, 2011, 15, R57.	5.8	51
206	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. Annals of the American Thoracic Society, 2015, 12, 1482-1489.	3.2	51
207	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
208	What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open, 2021, 11, e043887.	1.9	51
209	Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. European Journal of Clinical Microbiology and Infectious Diseases, 1997, 16, 789-796.	2.9	50
210	Demographics, guidelines, and clinical experience in severe community-acquired pneumonia. Critical Care, 2008, 12, S2.	5.8	50
211	Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2010, 65, 1330-1346.	3.0	50
212	Acinetobacter baumannii Infections in the ICU. Chest, 1999, 115, 1226-1229.	0.8	49
213	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. International Journal of Antimicrobial Agents, 2014, 43, 423-430.	2.5	48
214	Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents, 2020, 56, 106184.	2.5	48
215	Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy. European Radiology, 2021, 31, 1090-1099.	4.5	48
216	Impact of Nosocomial Infections on Outcome: Myths and Evidence. Infection Control and Hospital Epidemiology, 1999, 20, 392-394.	1.8	47

#	Article	IF	CITATIONS
217	Risk Factors for Ventilator-associated Pneumonia by Pseudomonas aeruginosa in Presence of Recent Antibiotic Exposure. Anesthesiology, 2006, 105, 709-714.	2.5	47
218	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infectious Diseases, 2012, 12, 152.	2.9	47
219	Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Critical Care, 2011, 15, R66.	5.8	46
220	Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clinical Microbiology and Infection, 2016, 22, 359-364.	6.0	46
221	A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients With Severe Bacterial Infections. Chest, 2020, 158, 929-938.	0.8	46
222	Polymicrobial bacteremia in critically ill patients. Intensive Care Medicine, 1993, 19, 22-25.	8.2	44
223	Mid-Regional Pro-Adrenomedullin (MR-proADM) as a Biomarker for Sepsis and Septic Shock: Narrative Review. Healthcare (Switzerland), 2018, 6, 110.	2.0	44
224	Strengthening ICU health security for a coronavirus epidemic. Intensive and Critical Care Nursing, 2020, 57, 102812.	2.9	44
225	Bench-to-bedside review: Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Critical Care, 2005, 9, 259.	5.8	43
226	Patient to Nurse Ratio and Risk of Ventilator-Associated Pneumonia in Critically Ill Patients. American Journal of Critical Care, 2011, 20, e1-e9.	1.6	43
227	Infection of Pulmonary Artery Catheters. Chest, 1993, 103, 132-136.	0.8	42
228	A European care bundle for management of ventilator-associated pneumonia. Journal of Critical Care, 2011, 26, 3-10.	2.2	42
229	The role of mannose-binding lectin in pneumococcal infection. European Respiratory Journal, 2013, 41, 131-139.	6.7	42
230	ESCMID generic competencies in antimicrobial prescribing and stewardship: towards a European consensus. Clinical Microbiology and Infection, 2019, 25, 13-19.	6.0	42
231	Invasive Aspergillosis: A Life-Threatening Complication of Short-Term Steroid Treatment. Annals of Pharmacotherapy, 1995, 29, 1235-1237.	1.9	41
232	FDA Evaluation of Antimicrobials. Chest, 2005, 127, 2298-2299.	0.8	41
233	Endocarditis and pericarditis complicating pneumococcal bacteraemia, with special reference to the adhesive abilities of pneumococci: results from a prospective study. Clinical Microbiology and Infection, 2006, 12, 338-344.	6.0	41
234	Assessing predictive accuracy for outcomes of ventilator-associated events in an international cohort: the EUVAE study. Intensive Care Medicine, 2018, 44, 1212-1220.	8.2	41

#	Article	IF	CITATIONS
235	Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial. Critical Care, 2020, 24, 74.	5.8	41
236	Radiologic Progression of Pulmonary Infiltrates Predicts a Worse Prognosis in Severe Community-Acquired Pneumonia Than Bacteremia. Chest, 2009, 135, 165-172.	0.8	40
237	Nurses' Knowledge of Evidence-Based Guidelines for the Prevention of Surgical Site Infection. Worldviews on Evidence-Based Nursing, 2010, 7, 16-24.	2.9	40
238	Severe 2009 A/H1N1v influenza in pregnant women in Spain*. Critical Care Medicine, 2011, 39, 945-951.	0.9	40
239	COVID-19-Associated Pulmonary Aspergillosis (CAPA). Journal of Intensive Medicine, 2021, 1, 71-80.	2.1	40
240	Lower Respiratory Tract Infections Following Cardiac Arrest and Cardiopulmonary Resuscitation. Clinical Infectious Diseases, 1995, 21, 310-314.	5.8	39
241	Early observational research and registries during the 2009–2010 influenza A pandemic. Critical Care Medicine, 2010, 38, e120-e132.	0.9	39
242	First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain. Medicina Intensiva, 2011, 35, 208-216.	0.7	39
243	Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. European Respiratory Journal, 2014, 43, 545-553.	6.7	39
244	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. Respiratory Care, 2016, 61, 1008-1014.	1.6	39
245	Community-acquired bacterial pneumonia in adults: An update. Indian Journal of Medical Research, 2020, 151, 287.	1.0	39
246	Ventilator-associated respiratory infection following lung transplantation. European Respiratory Journal, 2015, 45, 726-737.	6.7	38
247	Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 167-169.	1.4	38
248	Hospital-acquired pneumonia guidelines in Europe: a review of their status and future development. Journal of Antimicrobial Chemotherapy, 2007, 60, 206-213.	3.0	37
249	Impact of the emergence of non-vaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clinical Microbiology and Infection, 2013, 19, 385-391.	6.0	37
250	Etiology of Ventilator-Associated Pneumonia. Clinics in Chest Medicine, 2005, 26, 87-95.	2.1	36
251	Effects of Immunocompromise and Comorbidities on Pneumococcal Serotypes Causing Invasive Respiratory Infection in Adults: Implications for Vaccine Strategies. Clinical Infectious Diseases, 2013, 57, 1722-1730.	5.8	36
252	Invasive candidiasis: from mycobiome to infection, therapy, and prevention. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1221-1226.	2.9	36

#	Article	IF	CITATIONS
253	Diagnosis and outcome of acuteÂrespiratory failure in immunocompromised patients afterÂbronchoscopy. European Respiratory Journal, 2019, 54, 1802442.	6.7	36
254	Elevation of creatine kinase is associated with worse outcomes in 2009 pH1N1 influenzaÂA infection. Intensive Care Medicine, 2012, 38, 1152-1161.	8.2	35
255	The value of polyurethane-cuffed endotracheal tubes to reduce microaspiration and intubation-related pneumonia: a systematic review of laboratory and clinical studies. Critical Care, 2016, 20, 203.	5.8	35
256	Evaluation of culture techniques for identification of catheter-related infection in hemodialysis patients. European Journal of Clinical Microbiology and Infectious Diseases, 1989, 8, 620-622.	2.9	34
257	<i>Pseudomonas aeruginosa</i> Nosocomial Pneumonia: Impact of Pneumonia Classification. Infection Control and Hospital Epidemiology, 2015, 36, 1190-1197.	1.8	34
258	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
259	DIAGNOSTIC TESTING FOR VENTILATOR-ASSOCIATED PNEUMONIA. Clinics in Chest Medicine, 1999, 20, 671-679.	2.1	33
260	Combination antibiotic therapy for community-acquired pneumonia. Annals of Intensive Care, 2011, 1, 48.	4.6	33
261	AME evidence series 001—The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital. Journal of Thoracic Disease, 2016, 8, 2654-2665.	1.4	33
262	Diagnosing invasive pulmonary aspergillosis in ICU patients: putting the puzzle together. Current Opinion in Critical Care, 2019, 25, 430-437.	3.2	33
263	Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characterisation protocol: a prospective, multinational, multicentre, observational study. ERJ Open Research, 2022, 8, 00552-2021.	2.6	33
264	SEVERE PULMONARY HYPERTENSION IN IDIOPATHIC PULMONARY FIBROSIS. Chest, 2006, 130, 151S.	0.8	32
265	Feasibility of real-time polymerase chain reaction in whole blood to identify Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease, 2008, 61, 72-75.	1.8	32
266	Is Candida really a threat in the ICU?. Current Opinion in Critical Care, 2008, 14, 600-604.	3.2	32
267	Severe community-acquired pneumonia and PIRO: A new paradigm of management. Current Infectious Disease Reports, 2009, 11, 343-348.	3.0	32
268	Update in Community-acquired and Nosocomial Pneumonia 2009. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 782-787.	5.6	32
269	Severe sepsis in community-acquired pneumonia — Early recognition and treatment. European Journal of Internal Medicine, 2012, 23, 412-419.	2.2	32
270	Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey. Critical Care, 2013, 17, R289.	5.8	32

#	Article	IF	CITATIONS
271	Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy. Medicina Intensiva, 2013, 37, 320-326.	0.7	32
272	Sepsis and septic shock in low-income and middle-income countries: need for a different paradigm. International Journal of Infectious Diseases, 2016, 48, 120-122.	3.3	32
273	Severe influenza: overview in critically ill patients. Current Opinion in Critical Care, 2019, 25, 449-457.	3.2	32
274	Improving survival for sepsis: On the cutting edge *. Critical Care Medicine, 2003, 31, 2807-2808.	0.9	31
275	Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia. European Respiratory Review, 2007, 16, 33-39.	7.1	31
276	Severity assessment tools in ICU patients with 2009 Influenza A (H1N1) pneumonia. Clinical Microbiology and Infection, 2012, 18, 1040-1048.	6.0	31
277	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. Surgical Infections, 2017, 18, 846-853.	1.4	31
278	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with communityâ€acquired pneumonia. Respirology, 2020, 25, 543-551.	2.3	31
279	Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin. Intensive Care Medicine, 2020, 46, 766-770.	8.2	31
280	Therapy of ventilator-associated pneumonia: the Tarragona Strategy. Clinical Microbiology and Infection, 2001, 7, 32-33.	6.0	30
281	Improvement of antibiotic therapy and ICU survival in severe non-pneumococcal community-acquired pneumonia: a matched case–control study. Critical Care, 2015, 19, 335.	5.8	30
282	Precision medicine for the treatment of severe pneumonia in intensive care. Expert Review of Respiratory Medicine, 2016, 10, 297-316.	2.5	30
283	Severe community-acquired pneumonia: optimal management. Current Opinion in Infectious Diseases, 2017, 30, 240-247.	3.1	30
284	Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 95-104.	2.9	30
285	Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights. Expert Review of Clinical Pharmacology, 2019, 12, 635-642.	3.1	30
286	Secondary infections in mechanically ventilated patients with COVID-19: An overlooked matter?. Revista Espanola De Quimioterapia, 2021, 34, 330-336.	1.3	30
287	Clinical approach to the patient with suspected ventilator-associated pneumonia. Respiratory Care, 2005, 50, 965-74; discussion 974.	1.6	30
288	Management of ventilator-associated pneumonia in aÂmultidisciplinary intensive care unit: does trauma make aÂdifference?. Intensive Care Medicine, 2007, 33, 1387-1395.	8.2	29

#	Article	IF	CITATIONS
289	COPD patients with ventilator-associated pneumonia: implications for management. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 2403-2411.	2.9	29
290	Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome. Critical Care, 2016, 20, 337.	5.8	29
291	Implementing a care bundle approach reduces ventilator-associated pneumonia and delays ventilator-associated tracheobronchitis in children: differences according to endotracheal or tracheostomy devices. International Journal of Infectious Diseases, 2016, 52, 43-48.	3.3	28
292	Ageâ€related risk factors for bacterial aetiology in communityâ€acquired pneumonia. Respirology, 2016, 21, 1472-1479.	2.3	28
293	Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: an international ID-IRI survey. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2323-2334.	2.9	28
294	Current aspects in sepsis approach. Turning things around. Revista Espanola De Quimioterapia, 2018, 31, 298-315.	1.3	28
295	Acinetobacter baumannii: a threat for the ICU?. Intensive Care Medicine, 2003, 29, 350-351.	8.2	27
296	Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Medicine, 2006, 32, 971-980.	8.2	27
297	Severe sepsis mortality prediction with relevance vector machines. , 2011, 2011, 100-3.		27
298	The Relevance of Drug Volume of Distribution in Antibiotic Dosing. Current Pharmaceutical Biotechnology, 2011, 12, 1996-2001.	1.6	27
299	Cerebral aspergillosis in adult critically ill patients: a descriptive report of 10 patients from the AspICU cohort. International Journal of Antimicrobial Agents, 2014, 43, 165-169.	2.5	27
300	Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?. Expert Review of Respiratory Medicine, 2019, 13, 787-798.	2.5	27
301	Beneficial and harmful outcomes of tocilizumab in severe COVIDâ€19: A systematic review and metaâ€analysis. Pharmacotherapy, 2021, 41, 884-906.	2.6	27
302	Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care. Expert Opinion on Pharmacotherapy, 2006, 7, 1555-1569.	1.8	26
303	IMPACT OF ANTIBIOTIC GUIDELINE COMPLIANCE ON DURATION OF MECHANICAL VENTILATION IN CRITICALLY ILL PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA. Chest, 2006, 130, 100S.	0.8	26
304	We should be measuring genomic bacterial load and virulence factors. Critical Care Medicine, 2010, 38, S656-S662.	0.9	26
305	Imbalanced pro- and anti-Th17 responses (IL-17/granulocyte colony-stimulating factor) predict fatal outcome in 2009 pandemic influenza. Critical Care, 2011, 15, 448.	5.8	26
306	Prevention of VAP: Is Zero Rate Possible?. Clinics in Chest Medicine, 2011, 32, 591-599.	2.1	26

#	Article	IF	CITATIONS
307	Severe pandemic (H1N1)v influenza A infection: Report on the first deaths in Spain. Respirology, 2011, 16, 78-85.	2.3	26
308	Evolution Over a 15-Year Period of Clinical Characteristics and Outcomes of Critically Ill Patients With Community-Acquired Bacteremia*. Critical Care Medicine, 2013, 41, 76-83.	0.9	26
309	Management of infections in critically ill returning travellers in the intensive care unit—l: considerations on infection control and transmission of resistance. International Journal of Infectious Diseases, 2016, 48, 113-117.	3.3	26
310	An international perspective on hospitalized patients with viral community-acquired pneumonia. European Journal of Internal Medicine, 2019, 60, 54-70.	2.2	26
311	Laboratory diagnosis of catheter-related bacteremia. Scandinavian Journal of Infectious Diseases, 1991, 23, 583-588.	1.5	25
312	E. coli O104:H4 outbreak and haemolytic–uraemic syndrome. Medicina Intensiva, 2012, 36, 576-583.	0.7	25
313	Severe sepsis mortality prediction with logistic regression over latent factors. Expert Systems With Applications, 2012, 39, 1937-1943.	7.6	25
314	The clinical positioning of telavancin in Europe. International Journal of Antimicrobial Agents, 2015, 45, 213-220.	2.5	25
315	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. Journal of Infection, 2016, 73, 419-426.	3.3	25
316	Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 785-794.	2.9	25
317	COVID-19: First Do No Harm. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1324-1325.	5.6	25
318	Acute Renal Failure following Massive Mannitol Infusion. Nephron, 1989, 53, 377-378.	1.8	24
319	Evaluation of culture techniques for diagnosis of catheter-related sepsis in critically ill patients. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 1192-1193.	2.9	24
320	Mortality as an Outcome in Hospital-Acquired Pneumonia. Infection Control and Hospital Epidemiology, 1998, 19, 795-797.	1.8	24
321	Normativa SEPAR: neumonÃa nosocomial. Archivos De Bronconeumologia, 2011, 47, 510-520.	0.8	24
322	Mortality and Regional Oxygen Saturation Index in Septic Shock Patients: A Pilot Study. Journal of Trauma, 2011, 70, 1145-1152.	2.3	24
323	Direct association between pharyngeal viral secretion and host cytokine response in severe pandemic influenza. BMC Infectious Diseases, 2011, 11, 232.	2.9	24
324	Infections and Use of Antibiotics in Patients Admitted for Severe Acute Pancreatitis: Data from the EPIC II Study. Surgical Infections, 2014, 15, 394-398.	1.4	24

#	Article	IF	CITATIONS
325	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transplant Infectious Disease, 2019, 21, e13141.	1.7	24
326	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. Clinical Infectious Diseases, 2019, 69, 1912-1918.	5.8	24
327	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. Chest, 2021, 159, 58-72.	0.8	24
328	Nosocomial pneumonia in critically ill comatose patients: need for a differential therapeutic approach. European Respiratory Journal, 1992, 5, 1249-53.	6.7	24
329	Appropriateness isÂCritical. Critical Care Clinics, 2011, 27, 35-51.	2.6	23
330	What is new in the prevention of ventilator-associated pneumonia?. Current Opinion in Pulmonary Medicine, 2011, 17, 155-159.	2.6	23
331	The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 2155-2163.	2.9	23
332	As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?. Drugs, 2019, 79, 1729-1737.	10.9	23
333	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. Infectious Diseases and Therapy, 2020, 9, 701-705.	4.0	23
334	Management of ventilator-associated pneumonia caused by multiresistant bacteria. Current Opinion in Critical Care, 2007, 13, 45-50.	3.2	22
335	Viral load at diagnosis and influenza A H1N1 (2009) disease severity in children. Influenza and Other Respiratory Viruses, 2012, 6, e89-92.	3.4	22
336	Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the pre-infection period: A pilot study. Medicina Intensiva, 2012, 36, 257-263.	0.7	22
337	The Value of E-Learning for the Prevention of Healthcare-Associated Infections. Infection Control and Hospital Epidemiology, 2016, 37, 1052-1059.	1.8	22
338	Update in COVID-19 in the intensive care unit from the 2020 HELLENIC Athens International symposium. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 723-730.	1.4	22
339	Managing adult patients with infectious diseases in emergency departments: international ID-IRI study. Journal of Chemotherapy, 2021, 33, 302-318.	1.5	22
340	Trauma, head injury, and neurosurgery infections. Seminars in Respiratory Infections, 2000, 15, 280-286.	1.3	22
341	Optimal Therapy for Methicillin-Resistant Staphylococcus aureus Pneumonia. Chest, 2006, 130, 938-940.	0.8	21
342	Diagnosis of ventilator-associated pneumonia: is there a gold standard and a simple approach?. Current Opinion in Infectious Diseases, 2008, 21, 174-178.	3.1	21

#	Article	IF	CITATIONS
343	The role of nurses working in emergency and critical care environments in the prevention of intravascular catheter-related bloodstream infections. International Emergency Nursing, 2009, 17, 60-68.	1.5	21
344	Assessing Severity of Patients with Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2012, 33, 272-283.	2.1	21
345	First influenza season after the 2009 pandemic influenza: characteristics of intensive care unit admissions in adults and children in Vall d'Hebron Hospital. Clinical Microbiology and Infection, 2012, 18, 374-380.	6.0	21
346	Serum immunoglobulins in the infected and convalescent phases in community-acquired pneumonia. Respiratory Medicine, 2013, 107, 2038-2045.	2.9	21
347	Influenza and associated co-infections in critically ill immunosuppressed patients. Critical Care, 2019, 23, 152.	5.8	21
348	Effect of enriched thioglycolate on direct examination of respiratory specimens and guiding initial empirical therapy in intubated patients with pneumonia: A prospective, randomized study. Critical Care Medicine, 2002, 30, 311-314.	0.9	20
349	Choosing the right combination therapy in severe community-acquired pneumonia. Critical Care, 2006, 10, 115.	5.8	20
350	Why should we measure bacterial load when treating community-acquired pneumonia?. Current Opinion in Infectious Diseases, 2011, 24, 137-141.	3.1	20
351	Infections, antibiotic treatment and mortality in patients admitted to ICUs in countries considered to have high levels of antibiotic resistance compared to those with low levels. BMC Infectious Diseases, 2014, 14, 513.	2.9	20
352	Cardiac arrest among patients with infections: causes, clinical practice and research implications. Clinical Microbiology and Infection, 2017, 23, 730-735.	6.0	20
353	Human metapneumovirus as cause of severe community-acquired pneumonia in adults: insights from a ten-year molecular and epidemiological analysis. Annals of Intensive Care, 2019, 9, 86.	4.6	20
354	Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives. Microorganisms, 2021, 9, 1154.	3.6	20
355	Prevention of infection in the intensive care unit: current advances and opportunities for the future. Current Opinion in Critical Care, 2002, 8, 461-464.	3.2	19
356	Nosocomial lung infections in adult intensive care units. Microbes and Infection, 2004, 6, 1004-1014.	1.9	19
357	New Treatment Options for Infections Caused by Multiresistant Strains ofPseudomonas aeruginosaand Other Nonfermenting Gram-Negative Bacilli. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 151-158.	2.1	19
358	How to approach and treat VAP in ICU patients. BMC Infectious Diseases, 2014, 14, 211.	2.9	19
359	What if there were no new antibiotics? A look at alternatives. Expert Review of Clinical Pharmacology, 2016, 9, 1547-1555.	3.1	19
360	Assessing prediction accuracy for outcomes of ventilator-associated events and infections in critically ill children: a prospective cohort study. Clinical Microbiology and Infection, 2018, 24, 732-737.	6.0	19

#	Article	IF	CITATIONS
361	Clinical diagnosis of ventriculostomy-related infections. Lancet, The, 1994, 344, 1015-1016.	13.7	18
362	Survey of Ferroxidase Expression and Siderophore Production in Clinical Isolates of Pseudomonas aeruginosa. Journal of Clinical Microbiology, 2004, 42, 2806-2809.	3.9	18
363	Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza <scp>A</scp> (<scp>H</scp> 1 <scp>N</scp> 1). Journal of the American Geriatrics Society, 2013, 61, 350-356.	2.6	18
364	Infection control bundles in intensive care: an international cross-sectional survey in low- and middle-income countries. Journal of Hospital Infection, 2019, 101, 248-256.	2.9	18
365	Factors associated with ventilator-associated events: an international multicenter prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1693-1699.	2.9	18
366	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1513-1525.	2.9	18
367	Solid organ transplantation from donors with recent or current SARS-CoV-2 infection: A systematic review. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101098.	1.4	18
368	Optimal use of antibiotics for intubationassociated pneumonia. Intensive Care Medicine, 2001, 27, 337-339.	8.2	17
369	Impact of Nonexacerbated COPD on Mortality in Critically Ill Patients. Chest, 2011, 139, 1354-1360.	0.8	17
370	Which algorithm diagnoses invasive pulmonary aspergillosis best in ICU patients with COPD?. European Respiratory Journal, 2017, 50, 1700532.	6.7	17
371	Evidence supporting recommendations from international guidelines on treatment, diagnosis, and prevention of HAP and VAP in adults. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 483-491.	2.9	17
372	Lack of usefulness of blood cultures to diagnose ventilator-associated pneumonia. European Respiratory Journal, 1991, 4, 1020.	6.7	17
373	Appropriate Antibiotic Treatment for Pneumonia. Clinical Infectious Diseases, 2000, 31, 1313-1314.	5.8	16
374	Risk factors for pneumonia in the intubated patient. Infectious Disease Clinics of North America, 2003, 17, 697-705.	5.1	16
375	De-escalation in lower respiratory tract infections. Current Opinion in Pulmonary Medicine, 2006, 12, 364-368.	2.6	16
376	Early management of sepsis with emphasis on early goal directed therapy: AME evidence series 002. Journal of Thoracic Disease, 2017, 9, 392-405.	1.4	16
377	Nefer, Sinuhe and clinical research assessing post COVID-19 condition. European Respiratory Journal, 2021, 57, 2004423.	6.7	16
378	Linezolid and Vancomycin for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest, 2004, 126, 315-316.	0.8	15

#	Article	IF	CITATIONS
379	Gram-negative bacterial pneumonia: aetiology and management. Current Opinion in Internal Medicine, 2006, 5, 358-364.	1.5	15
380	Association between 4G/5G polymorphism of the plasminogen activator inhibitorÂ1 gene with stroke or encephalopathy after cardiac surgery. Intensive Care Medicine, 2006, 32, 668-675.	8.2	15
381	Community acquired infections among refugees leading to Intensive Care Unit admissions in Turkey. International Journal of Infectious Diseases, 2017, 58, 111-114.	3.3	15
382	Limiting ventilator-associated complications in ICU intubated subjects: strategies to prevent ventilator-associated events and improve outcomes. Expert Review of Respiratory Medicine, 2018, 12, 1037-1050.	2.5	15
383	Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1235-1240.	2.9	15
384	Managing sepsis in the era of precision medicine: challenges and opportunities. Expert Review of Anti-Infective Therapy, 2022, 20, 871-880.	4.4	15
385	Hospital-Acquired Pneumonia in the ICU Patient. Seminars in Respiratory and Critical Care Medicine, 1997, 18, 133-140.	2.1	14
386	Advances in the management of pneumonia in the intensive care unit: review of current thinking. Clinical Microbiology and Infection, 2005, 11, 30-38.	6.0	14
387	Targeted antibiotic management of ventilator-associated pneumonia. Clinical Microbiology and Infection, 2006, 12, 17-22.	6.0	14
388	Healthcare-associated infections. A useful concept?. Current Opinion in Critical Care, 2009, 15, 419-424.	3.2	14
389	Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: A comparison of the EUVAP and LATINVAP study cohorts. Medicina Intensiva, 2013, 37, 241-247.	0.7	14
390	Personalized medicine in severe influenza. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 893-897.	2.9	14
391	Postmortem microbiology sampling following death in hospital: an ESGFOR task force consensus statement. Journal of Clinical Pathology, 2019, 72, 329-336.	2.0	14
392	Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study. International Journal of Antimicrobial Agents, 2022, 60, 106591.	2.5	14
393	Severity of illness assessment for managing community-acquired pneumonia. Intensive Care Medicine, 2007, 33, 2043-2044.	8.2	13
394	Risk factors for Pseudomonas aeruginosa pneumonia in the early twenty-first century. Intensive Care Medicine, 2013, 39, 2204-2206.	8.2	13
395	Understanding the Concept of Health Care-Associated Pneumonia in Lung Transplant Recipients. Chest, 2015, 148, 516-522.	0.8	13
396	Influenza infection in the intensive care unit: Four years after the 2009 pandemic. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 177-183.	0.5	13

#	Article	IF	CITATIONS
397	High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: A matter of time?. Journal of Infection, 2021, 82, 186-230.	3.3	13
398	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. Current Opinion in Infectious Diseases, 2021, 34, 156-168.	3.1	13
399	Post-acute COVID-19 Syndrome (PACS): A public health emergency. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100882.	1.4	13
400	Ventilator-associated pneumonia management in critical illness. Current Opinion in Gastroenterology, 2011, 27, 160-166.	2.3	12
401	The relationship between ventilator-associated pneumonia and chronic obstructive pulmonary disease: what is the current evidence?. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 637-647.	2.9	12
402	Ventilator-associated pneumonia diagnosis: a prioritization exercise based on multi-criteria decision analysis. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 281-286.	2.9	12
403	Respiratory Mechanics and Outcomes in Immunocompromised Patients With ARDS. Chest, 2020, 158, 1947-1957.	0.8	12
404	Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials. Expert Review of Clinical Pharmacology, 2021, 14, 901-918.	3.1	12
405	Mortality as an Outcome in Hospital-Acquired Pneumonia. Infection Control and Hospital Epidemiology, 1998, 19, 795-797.	1.8	12
406	Diagnostic and prognostic prediction models in ventilator-associated pneumonia: Systematic review and meta-analysis of prediction modelling studies. Journal of Critical Care, 2022, 67, 44-56.	2.2	12
407	Cloxacillin-Induced Neutropenia. Journal of Infectious Diseases, 1986, 154, 372-372.	4.0	11
408	Specific problems of arterial, Swan-Ganz, and hemodialysis catheters. Nutrition, 1997, 13, 36S-41S.	2.4	11
409	Antibacterial Treatment of Invasive Mechanical Ventilation???Associated Pneumonia. Drugs and Aging, 2001, 18, 189-200.	2.7	11
410	Severe acute respiratory infections in the postpandemic era of H1N1. Current Opinion in Critical Care, 2012, 18, 441-450.	3.2	11
411	Primary Graft Dysfunction and Mortality Following Lung Transplantation: A Role for Proadrenomedullin Plasma Levels. American Journal of Transplantation, 2016, 16, 634-639.	4.7	11
412	Ventilator-associated events versus ventilator-associated respiratory infections—moving into a new paradigm or merging both concepts, instead?. Annals of Translational Medicine, 2018, 6, 425-425.	1.7	11
413	Candidemia in the patient with malignancy. Hospital Practice (1995), 2018, 46, 246-252.	1.0	11
414	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respiratory Medicine, 2018, 140, 115-121.	2.9	11

#	Article	IF	CITATIONS
415	Necrotic acral lesions and lung failure in a fatal case of COVIDâ€19. Australasian Journal of Dermatology, 2020, 61, e467-e468.	0.7	11
416	Treatment of nasal bridge ulceration related to protective measures for the COVID â€19 epidemic. International Wound Journal, 2020, 17, 1520-1522.	2.9	11
417	Compliance with Guidelines-Recommended Processes in Pneumonia: Impact of Health Status and Initial Signs. PLoS ONE, 2012, 7, e37570.	2.5	11
418	Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia. Infezioni in Medicina, 2017, 25, 311-319.	1.1	11
419	The COVID-19 vaccination acceptance/hesitancy rate and its determinants among healthcare workers of 91 Countries: A multicenter cross-sectional study EXCLI Journal, 2022, 21, 93-103.	0.7	11
420	Impact of using an indwelling introducer on diagnosis of Swan-Ganz pulmonary artery catheter colonization. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 71-75.	2.9	10
421	Prescription of Macrolides in Community-Acquired Pneumonia. Chest, 1998, 113, 1155-1158.	0.8	10
422	SEPAR Guidelines for Nosocomial Pneumonia. Archivos De Bronconeumologia, 2011, 47, 510-520.	0.8	10
423	Clostridium difficile in the ICU: Study of the incidence, recurrence, clinical characteristics and complications in a University Hospital. Medicina Intensiva, 2014, 38, 140-145.	0.7	10
424	Management of septic shock and severe infections in migrants and returning travelers requiring critical care. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 527-533.	2.9	10
425	Risk Factors for Mortality in 272 Patients With Lung Transplant: A Multicenter Analysis of 7 Intensive Care Units. Archivos De Bronconeumologia, 2017, 53, 421-426.	0.8	10
426	Prone positioning as a bridge to recovery from refractory hypoxaemia following lung transplantationâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 25, 292-296.	1.1	10
427	Improved survival among ICU-hospitalized patients with community-acquired pneumonia by unidentified organisms: a multicenter case–control study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 123-130.	2.9	10
428	Management of ventilator-associated pneumonia: Need for a personalized approach. Expert Review of Anti-Infective Therapy, 2018, 16, 641-653.	4.4	10
429	Neuraminidase inhibitors are effective and safe in reducing influenza complications: meta-analysis of randomized controlled trials European Journal of Internal Medicine, 2021, 86, 54-65.	2.2	10
430	Changing physicians' behavior in the intensive care unit *. Critical Care Medicine, 2002, 30, 2593-2594.	0.9	10
431	Early postoperative management of lung transplantation. Minerva Anestesiologica, 2014, 80, 1234-45.	1.0	10
432	Non-Pharmacological Prevention of Ventilator Associated Pneumonia. Archivos De Bronconeumologia, 2010, 46, 188-195.	0.8	9

#	Article	IF	CITATIONS
433	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. International Journal of Infectious Diseases, 2011, 15, e822-e827.	3.3	9
434	Impact of influenza season and environmental factors on the clinical presentation and outcome of invasive pneumococcal disease. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 177-186.	2.9	9
435	High flow oxygen cannula: the other side of the moon. Intensive Care Medicine, 2015, 41, 1673-1675.	8.2	9
436	Early and mid-term results of lung transplantation with donors 60 years and older. Interactive Cardiovascular and Thoracic Surgery, 2015, 20, 47-53.	1.1	9
437	Management of infections in critically ill returning travellers in the intensive care unit—II: clinical syndromes and special considerations in immunocompromised patients. International Journal of Infectious Diseases, 2016, 48, 104-112.	3.3	9
438	Infections in intensive care unit adult patients harboring multidrug-resistant Pseudomonas aeruginosa: implications for prevention and therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1097-1104.	2.9	9
439	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. European Respiratory Journal, 2017, 50, 1700013.	6.7	9
440	Outcomes for haematological cancer patients admitted to an intensive care unit in a university hospital. Australian Critical Care, 2018, 31, 363-368.	1.3	9
441	Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	9
442	Antimicrobial Stewardship in Hematological Patients at the intensive care unit: a global cross-sectional survey from the Nine-i Investigators Network. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 385-392.	2.9	9
443	Understanding resistance in enterococcal infections. Intensive Care Medicine, 2020, 46, 353-356.	8.2	9
444	Levels of evidence supporting European and American community-acquired pneumonia guidelines. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1159-1167.	2.9	9
445	Management of hypoxemia in SARS-CoV-2 infection: Lessons learned from one year of experience, with a special focus on silent hypoxemia. Journal of Intensive Medicine, 2021, 1, 26-30.	2.1	9
446	Acute respiratory failure in immunocompromised patients: outcome and clinical features according to neutropenia status. Annals of Intensive Care, 2020, 10, 146.	4.6	9
447	Plasma levels of mid-regional pro-adrenomedullin in sepsis are associated with risk of death. Minerva Anestesiologica, 2019, 85, 366-375.	1.0	9
448	Screening for antimicrobial-resistant Gram-negative bacteria in hospitalised patients, and risk of progression from colonisation to infection: Systematic review. Journal of Infection, 2022, 84, 119-130.	3.3	9
449	Plasma Levels of Mid-Regional Proadrenomedullin Accurately Identify H1N1pdm09 Influenza Virus Patients with Risk of Intensive Care Admission and Mortality in the Emergency Department. Journal of Personalized Medicine, 2022, 12, 84.	2.5	9
450	Single-Breath Counting Test Predicts Non-Invasive Respiratory Support Requirements in Patients with COVID-19 Pneumonia. Journal of Clinical Medicine, 2022, 11, 179.	2.4	9

#	Article	IF	CITATIONS
451	Presence of Polyclonal <i>Pseudomonas aeruginosa</i> in an Intensive Care Unit A 27-Month Prospective Study on Molecular Epidemiology. Infection Control and Hospital Epidemiology, 2001, 22, 720-723.	1.8	8
452	Safety in Critical Care and Pulmonary Medicine. Clinical Pulmonary Medicine, 2009, 16, 28-32.	0.3	8
453	Prevention of Ventilator-Associated Pneumonia: Can Knowledge and Clinical Practice Be Simply Assessed in a Large Institution?. Respiratory Care, 2013, 58, 1213-1219.	1.6	8
454	Chromogranin A levels and mortality in patients with severe sepsis. Biomarkers, 2015, 20, 171-176.	1.9	8
455	Theranostics in severe influenza. Lancet Respiratory Medicine,the, 2017, 5, 91-92.	10.7	8
456	Procalcitonin accurately predicts lung transplant adults with low risk of pulmonary graft dysfunction and intensive care mortality. Journal of Critical Care, 2018, 44, 142-147.	2.2	8
457	A European ECMMâ€ESCMID survey on goals and practices for mycobiota characterisation using nextâ€generation sequencing. Mycoses, 2019, 62, 1096-1099.	4.0	8
458	Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. , 2007, 33, 133-144.		8
459	The pneumonia severity index predicts time to clinical stability in patients with community-acquired pneumonia. International Journal of Tuberculosis and Lung Disease, 2006, 10, 739-43.	1.2	8
460	Gentamicin Pharmacokinetic Changes Related to Mechanical Ventilation. DICP: the Annals of Pharmacotherapy, 1989, 23, 923-924.	0.2	7
461	New perspectives in the diagnosis of nosocomial pneumonia. Current Opinion in Pulmonary Medicine, 1997, 3, 116-119.	2.6	7
462	Prevention of VAP: the whole is more than the sum of its parts. Intensive Care Medicine, 2008, 34, 985-7.	8.2	7
463	On the use of decision trees for ICU outcome prediction in sepsis patients treated with statins. , 2011, , .		7
464	Objetivos docentes en la formación de médicos residentes en trasplante de órganos sólidos. Medicina Intensiva, 2012, 36, 584-588.	0.7	7
465	Management of Pseudomonas aeruginosa pneumonia: one size does not fit all. Critical Care, 2014, 18, 136.	5.8	7
466	What's new in ventilator-associated pneumonia?. Intensive Care Medicine, 2015, 41, 1954-1956.	8.2	7
467	Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. Medicina Intensiva, 2016, 40, 474-482.	0.7	7
468	Predictors of choice of initial antifungal treatment in intraabdominal candidiasis. Clinical Microbiology and Infection, 2016, 22, 719-724.	6.0	7

#	Article	IF	CITATIONS
469	Severe viral pneumonia in adults: what is important for the ICU physician?. Hospital Practice (1995), 2017, 45, 131-134.	1.0	7
470	Pneumonia <i>versus</i> graft dysfunction as the cause of acute respiratory failure after lung transplant: a 4-year multicentre prospective study in 153 adults requiring intensive care admission. European Respiratory Journal, 2019, 54, 1801512.	6.7	7
471	Treatment of ventilator-associated pneumonia (VAP) caused by Acinetobacter: results of prospective and multicenter ID-IRI study. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 45-52.	2.9	7
472	Artificial Intelligence for clinical decision support in Critical Care, required and accelerated by COVID-19. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 691-693.	1.4	7
473	COVID-19, steroids and other immunomodulators: The jigsaw is not complete. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 699-701.	1.4	7
474	The effects of sedatives, neuromuscular blocking agents and opioids on ventilator-associated events. European Journal of Anaesthesiology, 2020, 37, 67-69.	1.7	7
475	Clinical Features and Outcomes of Monobacterial and Polybacterial Episodes of Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii. Antibiotics, 2022, 11, 892.	3.7	7
476	False Hypoxemia Induced by Leukocytosis. Critical Care Medicine, 1989, 17, 970.	0.9	6
477	Evaluation of Different Catheter Parts for Identification of Pulmonary Artery Catheter Colonisation. Scandinavian Journal of Infectious Diseases, 1991, 23, 655-656.	1.5	6
478	Presence of Polyclonal Pseudomonas aeruginosa in an Intensive Care Unit A 27-Month Prospective Study on Molecular Epidemiology. Infection Control and Hospital Epidemiology, 2001, 22, 720-723.	1.8	6
479	Top Ten List in Antibiotic Policy in the ICU. Chest, 2002, 122, 712-714.	0.8	6
480	PAI-1 gene: pharmacogenetic association of 4G/4G genotype with bleeding after cardiac surgery – pilot study. European Journal of Anaesthesiology, 2009, 26, 404-411.	1.7	6
481	Towards zero rate in healthcare-associated infections: one size shall not fit all Critical Care, 2013, 17, 139.	5.8	6
482	Antibiotic Stewardship in Hospital-Acquired Pneumonia. Chest, 2013, 143, 1195-1196.	0.8	6
483	"Salvage treatment―for infections by extensively- and pan-drug-resistant pathogens is common and often sub-optimal. Intensive Care Medicine, 2017, 43, 1164-1166.	8.2	6
484	Drivers and impact of antifungal therapy in critically ill patients with Aspergillus-positive respiratory tract cultures. International Journal of Antimicrobial Agents, 2017, 50, 529-535.	2.5	6
485	Kinetics of Serological Responses in Critically III Patients Hospitalized With 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009–2011. Journal of Infectious Diseases, 2018, 217, 1078-1088.	4.0	6
486	Emerging Technologies for Microbiologic Diagnosis of Sepsis: The Rapid Determination of Resistance to Antimicrobial Agents Should Be the Key. Clinical Infectious Diseases, 2021, 73, 1173-1175.	5.8	6

#	Article	IF	CITATIONS
487	Severe Community-Acquired Pneumonia. , 2001, , 611-623.		6
488	Antiseptic barrier caps in central line-associated bloodstream infections: A systematic review and meta-analysis. European Journal of Internal Medicine, 2022, , .	2.2	6
489	Jugular Vein Cannulation for Hemodialysis Access. Nephron, 1988, 50, 391-392.	1.8	5
490	Pneumonia in Head-Injured and Severe Trauma Patients. Seminars in Respiratory and Critical Care Medicine, 2002, 23, 435-442.	2.1	5
491	The simple and the simpler in pneumonia diagnosis. Critical Care, 2007, 11, 140.	5.8	5
492	Southern European Intensive Care Nurses' Knowledge of Evidence-Based Guidelines for Preventing Ventilator-Associated Pneumonia. Medicina Intensiva (English Edition), 2011, 35, 6-12.	0.2	5
493	Lung transplant: An emerging challenge in the ICU. Medicina Intensiva, 2012, 36, 504-505.	0.7	5
494	Impact of the 2009 influenza A H1N1 pandemic on invasive pneumococcal disease in adults. Scandinavian Journal of Infectious Diseases, 2014, 46, 185-192.	1.5	5
495	Pneumonia and Lung Ultrasound in the Intensive Care Unit. Chest, 2014, 145, 171A.	0.8	5
496	Septic shock in the era of precision medicine. Journal of Thoracic Disease, 2016, 8, 1022-1023.	1.4	5
497	Managing the oncologic patient with suspected pneumonia in the intensive care unit. Expert Review of Anti-Infective Therapy, 2016, 14, 943-960.	4.4	5
498	Implications of oxygenation variations in ventilated patients with respiratory infections. Minerva Anestesiologica, 2018, 84, 423-425.	1.0	5
499	Levels of evidence supporting clinical practice guidelines on invasive aspergillosis. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 903-913.	2.9	5
500	A novel id-iri score: development and internal validation of the multivariable community acquired sepsis clinical risk prediction model. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 689-701.	2.9	5
501	Quality of evidence supporting Surviving Sepsis Campaign Recommendations. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 497-502.	1.4	5
502	Understanding resistance in Pseudomonas. Intensive Care Medicine, 2020, 46, 350-352.	8.2	5
503	Alternative Regimens of Neuraminidase Inhibitors for Therapy of Hospitalized Adults with Influenza: A Systematic Review of Randomized Controlled Trials. Advances in Therapy, 2020, 37, 2646-2666.	2.9	5
504	Short-Acting Sedative-Analgesic Drugs Protect Against Development of Ventilator-Associated Events in Children: Secondary Analysis of the EUVAE Study. Respiratory Care, 2021, 66, 798-805.	1.6	5

#	Article	IF	CITATIONS
505	Aminoglycosides in Immunocompromised Critically Ill Patients With Bacterial Pneumonia and Septic Shock: A Post-Hoc Analysis of a Prospective Multicenter Multinational Cohort. Shock, 2020, 54, 731-737.	2.1	5
506	Human microbiome in respiratory diseases. Annals of Translational Medicine, 2017, 5, 248-248.	1.7	5
507	Peace, not war in Ukraine or anywhere else, please. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101068.	1.4	5
508	Top Ten List in Ventilator-Associated Pneumonia. Chest, 2003, 124, 1580-1583.	0.8	4
509	Silver-coated endotracheal tubes: Is the bactericidal effect time limited?. Critical Care Medicine, 2007, 35, 987.	0.9	4
510	Management of Ventilator-Associated Pneumonia. Infectious Disease Clinics of North America, 2009, 23, 521-533.	5.1	4
511	The sounds of cardiac arrest: Innovating to obtain an accurate record during in-hospital cardiac arrest. Resuscitation, 2012, 83, 1219-1222.	3.0	4
512	Usefulness of procalcitonin clearance as a prognostic biomarker in septic shock. A prospective pilot study. Medicina Intensiva (English Edition), 2012, 36, 475-480.	0.2	4
513	Antibiotic prescription for respiratory tract infections in ventilated patients: where are we heading?. Intensive Care Medicine, 2013, 39, 1644-1646.	8.2	4
514	An unusual case of organizing pneumonia and infection by P. jirovecii. Medicina Intensiva, 2013, 37, 299-300.	0.7	4
515	Impact of availability of guidelines and active surveillance in reducing the incidence of ventilator-associated pneumonia in Europe and worldwide. BMC Infectious Diseases, 2014, 14, 199.	2.9	4
516	Knowledge and management of endotracheal tube cuffs. International Journal of Nursing Studies, 2015, 52, 498-499.	5.6	4
517	Cost of nosocomial pneumonia: the example of vancomycin versus linezolid—shorter stay or fewer complications?. International Journal of Infectious Diseases, 2016, 51, 1-3.	3.3	4
518	Endomyocardial and pericardial aspergillosis in critically ill patients. Mycoses, 2017, 60, 576-580.	4.0	4
519	Evaluation of the quality of evidence supporting guideline recommendations for the nutritional management of critically ill adults. Clinical Nutrition ESPEN, 2020, 39, 144-149.	1.2	4
520	Severe palmar hyperkeratosis and hematochezia in <scp>COVID</scp> â€19. Dermatologic Therapy, 2020, 33, e14423.	1.7	4
521	Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department. BMC Pulmonary Medicine, 2020, 20, 83.	2.0	4
522	New insights into pneumonia in patients on prolonged mechanical ventilation: need for a new paradigm addressing dysbiosis. Jornal Brasileiro De Pneumologia, 2021, 47, e20210198.	0.7	4

#	Article	IF	CITATIONS
523	Inhaled antibiotics for treatment of adults with non-cystic fibrosis bronchiectasis: A systematic review and meta-analysis. European Journal of Internal Medicine, 2021, 90, 77-88.	2.2	4
524	Rotación cÃclica de antibióticos: ¿es oro todo lo que reluce?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2003, 21, 93-100.	0.5	4
525	Causes of non-adherence to therapeutic guidelines in severe community-acquired pneumonia. Revista Brasileira De Terapia Intensiva, 2015, 27, 44-50.	0.3	4
526	Nebulized Antibiotics for Healthcare- and Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 255-270.	2.1	4
527	Pneumonia in immunocompetent patients: combination antibiotic therapy. Minerva Anestesiologica, 2014, 80, 495-503.	1.0	4
528	Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis. Antibiotics, 2022, 11, 275.	3.7	4
529	Ventilator-associated events in children: A multicentre prospective cohort study. Anaesthesia, Critical Care & Pain Medicine, 2022, 41, 101072.	1.4	4
530	Central Vein Catheters for Hemodialysis. Nephron, 1989, 51, 296-296.	1.8	3
531	Aseptic Meningitis Associated with Muromonab-CD3. DICP: the Annals of Pharmacotherapy, 1990, 24, 1233-1233.	0.2	3
532	Aspiration Pneumonia. , 2002, , 239-255.		3
533	Antibiotic Use and the Risk of Pneumonia: 20 Years of Studies, but Where Are We Now?. Clinical Infectious Diseases, 2004, 38, 1409-1411.	5.8	3
534	Obesity and Critical Care. Clinical Pulmonary Medicine, 2009, 16, 202-211.	0.3	3
535	Emerging drugs for pneumococcal pneumonia. Expert Opinion on Emerging Drugs, 2011, 16, 459-477.	2.4	3
536	Solid organ transplant training objectives for residents. Medicina Intensiva (English Edition), 2012, 36, 584-588.	0.2	3
537	What is the Research Agenda in Ventilator-associated Pneumonia?. International Journal of Infectious Diseases, 2016, 51, 110-112.	3.3	3
538	Can We Achieve Zero Hospital-Acquired Pneumonia?. Current Treatment Options in Infectious Diseases, 2018, 10, 153-168.	1.9	3
539	Best practice for sepsis. Journal of Thoracic Disease, 2018, 10, 1280-1282.	1.4	3
540	Precision medicine for the treatment of sepsis: recent advances and future prospects. Expert Review of Precision Medicine and Drug Development, 2019, 4, 205-213.	0.7	3

#	Article	IF	CITATIONS
541	Ten tips for the intensive care management of transplanted lung patients. Intensive Care Medicine, 2019, 45, 371-373.	8.2	3
542	Acute respiratory failure among lung transplant adults requiring intensive care: Changing spectrum of causative organisms and impact of procalcitonin test in the diagnostic workup. Transplant Infectious Disease, 2020, 22, e13346.	1.7	3
543	On the Use of Graphical Models to Study ICU Outcome Prediction in Septic Patients Treated with Statins. Lecture Notes in Computer Science, 2012, , 98-111.	1.3	3
544	Cutaneous Endothelial Dysfunction and Complement Deposition in COVID-19. American Journal of Dermatopathology, 2021, 43, 237-238.	0.6	3
545	2021 adaptation of the editorial policy of Anaesthesia Critical Care and Pain Medicine (ACCPM). Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100957.	1.4	3
546	Invasive pulmonary aspergillosis in solidâ€organ transplant patients in the intensive care unit. Transplant Infectious Disease, 2022, 24, e13746.	1.7	3
547	Female representation in intensive care medicine: Challenges and perspectives from China. Journal of Intensive Medicine, 2022, 2, 89-91.	2.1	3
548	Community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 1995, 1, 183-7.	2.6	3
549	Challenges in Respiratory Syncytial Virus in Adults With Severe Community-acquired Pneumonia. Chest, 2022, 161, 1434-1435.	0.8	3
550	Pulmonary Embolism Due to an Indwelling Central Venous Catheter. Chest, 1991, 100, 1477-1478.	0.8	2
551	Bacteremia and Fungemia of Unknown Origin among Patients Receiving Intensive Care. Clinical Infectious Diseases, 1992, 15, 184-184.	5.8	2
552	Nonpharmacologic Strategies for Preventing Nosocomial Pneumonia. Clinical Pulmonary Medicine, 1997, 4, 141-147.	0.3	2
553	Ventilator-Associated Pneumonia, Percutaneous Tracheostomy, and Antimicrobial Prophylaxis. Chest, 2004, 126, 1382-1383.	0.8	2
554	Optimal outcome in patients with community-acquired pneumonia: Take the main course before the dessert*. Critical Care Medicine, 2005, 33, 1149.	0.9	2
555	Case 15-2007: A Woman with Asthma and Cardiorespiratory Arrest. New England Journal of Medicine, 2007, 357, 420-421.	27.0	2
556	New Developments in Therapeutic Agents for Legionnaires Disease. Anti-Infective Agents in Medicinal Chemistry, 2007, 6, 228-242.	0.6	2
557	Pneumonia Due toPseudomonas aeruginosa. , 0, , 93-105.		2
558	Mono versus combination antibiotic therapy: Who is right?. Critical Care Medicine, 2007, 35, 2668.	0.9	2

#	Article	IF	CITATIONS
559	Ventilator-associated pneumonia prevalence: To benchmark or not to benchmark*. Critical Care Medicine, 2009, 37, 2657-2659.	0.9	2
560	PIRO score for community-acquired pneumonia: A new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia. Critical Care Medicine, 2010, 38, 1236-1237.	0.9	2
561	Assess Dental Plaque and Suction-Extricated Bacteria Adequately: Response. Chest, 2010, 137, 500-501.	0.8	2
562	Predicting treatment failure in severe sepsis and septic shock: looking for the Holy Grail. Critical Care, 2013, 17, 180.	5.8	2
563	Update in Pulmonary Infections 2012. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 1061-1066.	5.6	2
564	Reply to Rhodes et al. Clinical Infectious Diseases, 2014, 59, 907-908.	5.8	2
565	Is There a Role for Inhaled Antibiotics in the Treatment of Ventilator-Associated Infections?. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 359-370.	2.1	2
566	2017 Global survey on nebulization of antimicrobial agents in mechanically ventilated patients—SANEME 2 study protocol. Journal of Emergency and Critical Care Medicine, 2017, 1, 5-5.	0.7	2
567	Precision medicine and aerosolization in mechanically ventilated adults. Journal of Thoracic Disease, 2018, 10, S3111-S3114.	1.4	2
568	Implementation of infection control bundles in intensive care units: which parameters are applicable in low-to-middle income countries?. Journal of Hospital Infection, 2019, 101, 245-247.	2.9	2
569	Etiologies and Outcomes of Acute Respiratory Failure in Solid Organ Transplant Recipients: Insight Into the EFRAIM Multicenter Cohort. Transplantation Proceedings, 2020, 52, 2980-2987.	0.6	2
570	Bacteremia in critically ill immunocompromised patients with acute hypoxic respiratory failure: A post-hoc analysis of a prospective multicenter multinational cohort. Journal of Critical Care, 2021, 64, 114-119.	2.2	2
571	What is the most adequate non-invasive oxygen support for acute hypoxaemic respiratory failure due to COVID-19?. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100909.	1.4	2
572	Convalescent plasma for SARS-CoV-2 infection: Win or Learn. European Respiratory Journal, 2021, , 2102076.	6.7	2
573	Community-Acquired Pneumonia in Adults: What's New Focusing on Epidemiology, Microorganisms and Diagnosis?. Erciyes Medical Journal, 2018, 40, 177-182.	0.0	2
574	Rapid diagnosis of hemodialysis catheter sepsis. Clinical Nephrology, 1989, 31, 118.	0.7	2
575	Systemic infections associated with tattoos or permanent makeup: A systematic review. Medicina ClÃnica (English Edition), 2022, 158, 159-166.	0.2	2
576	Late Appearance of Pneumothorax after Subclavian Catherization for Hemodialysis. Nephron, 1988, 49, 172-172.	1.8	1

#	Article	IF	CITATIONS
577	USEFULNESS OF TIP CULTURES TO DETECT PULMONARY ARTERY CATHETER-RELATED INFECTIONS. Lancet, The, 1989, 334, 1224.	13.7	1
578	Severe Bleeding in Postoperative Patients with Infections. Annals of Pharmacotherapy, 1994, 28, 1308-1309.	1.9	1
579	Antimicrobial Use in Patients with Positive Intravascular Catheter Cultures: A Six-Month Prospective Survey in a Teaching Hospital. Infection Control and Hospital Epidemiology, 1996, 17, 668-669.	1.8	1
580	Role of the Microbiology Laboratory in the Diagnosis of Ventilator-Associated Pneumonia. , 0, , 43-62.		1
581	EFFICAY OF DORIPENEM IN NOSOCOMIAL PNEUMONIA: NON-VENTILATOR-ASSOCIATED AND VENTILATOR-ASSOCIATED PNEUMONIA. Chest, 2007, 132, 498C.	0.8	1
582	Assessment of severity in patients with community-acquired pneumonia: reply to letter by Challen et al Intensive Care Medicine, 2008, 34, 968-968.	8.2	1
583	Finding the hidden target in Pseudomonas aeruginosa management*. Critical Care Medicine, 2008, 36, 2675-2676.	0.9	1
584	Genetic variability at the surfactant proteins A and D in susceptibility and severity of pneumonia. Critical Care, 2010, 14, P82.	5.8	1
585	Ventilator-associated Pneumonia and Cuff Shape. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 485-486.	5.6	1
586	E. coli O104:H4 outbreak and haemolytic–uraemic syndrome. Medicina Intensiva (English Edition), 2012, 36, 576-583.	0.2	1
587	The authors reply. Critical Care Medicine, 2014, 42, e314-e315.	0.9	1
588	Complications in the Immediate Postoperatory of Lung Transplantation: Three Years of Practice at a High-Experienced Center. Chest, 2014, 145, 631A.	0.8	1
589	Ecological implications of different antibiotic strategies in the management of ventilator-associated pneumonia: in medio stat virtus. Minerva Anestesiologica, 2017, 83, 540-542.	1.0	1
590	Infection control bundles in low-middle income countries: an international cross-sectional survey (study protocol). Journal of Emergency and Critical Care Medicine, 2018, 2, 40-40.	0.7	1
591	Infectious diseases: the 10 common truths I never believed. Intensive Care Medicine, 2019, 45, 243-245.	8.2	1
592	Valuing antibiotics: The role of the hospital clinician. International Journal of Antimicrobial Agents, 2019, 54, 16-22.	2.5	1
593	Clinical Practice Guidelines Versus Actual Clinical Practice: The Pneumonia Paradigm. Clinical Infectious Diseases, 2021, 73, e1611-e1612.	5.8	1
594	How to improve research on management of critically ill patients: Lessons learned from negative randomised clinical trials in the intensive care unit. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 173-174.	1.4	1

#	Article	IF	CITATIONS
595	Systemic infections associated with tattoos or permanent makeup: A systematic review. Medicina ClÃnica, 2022, 158, 159-166.	0.6	1
596	Antimicrobial Use in Patients with Positive Intravascular Catheter Cultures: A Six-Month Prospective Survey in a Teaching Hospital. Infection Control and Hospital Epidemiology, 1996, 17, 668-669.	1.8	1
597	TOp TEn resistant Microorganisms at intensive care unit: a 2018 global expert survey (TOTEM study) Tj ETQq1	1 0.784314 0.7	rgBT /Overic
598	Clinical Management of COVID-19: Conceptual Framework. Infectious Diseases and Clinical Microbiology, 2020, 2, 46-47.	0.3	1
599	Infection of Pulmonary Arterial Catheter and Peripheral Arterial Catheter. , 2001, , 561-571.		1
600	Current Dilemmas in the Management of Adults with Severe Community-Acquired Pneumonia. , 2003, , 162-174.		1
601	Candida Pneumonia in Patients with Hematological Neoplasia. , 2011, , 349-356.		1
602	Aetiopathogenesis of VAP revisited. , 2011, , 1-10.		1
603	Microbiology of bacterial CAP using traditional and molecular techniques. , 2014, , 25-41.		1
604	Treatment of Legionnaires' Disease. , 0, , 8-14.		1
605	Crisis Level ICU Triage Is About Saving Lives. Critical Care Medicine, 2021, 49, e102-e103.	0.9	1
606	Critical appraisal of international adult bronchiectasis guidelines using the AGREE II tool. European Journal of Internal Medicine, 2022, , .	2.2	1
607	LISTERIOSIS. Lancet, The, 1985, 326, 951.	13.7	0
608	Theophylline Plasma Concentrations and Silicone Central Venous Catheter: A Potential Source of Error. DICP: the Annals of Pharmacotherapy, 1990, 24, 324-324.	0.2	0
609	Effect of Continuous Arteriovenous Hemodialysis on Ganciclovir Pharmacokinetics. DICP: the Annals of Pharmacotherapy, 1990, 24, 544-545.	0.2	0
610	Ventilator-Associated Pneumonia. Chest, 1994, 106, 646.	0.8	0
611	Antimicrobial Use in Patients With Positive Intravascular Catheter Cultures A Six-Month Prospective Survey in a Teaching Hospital. Infection Control and Hospital Epidemiology, 1996, 17, 668-669.	1.8	0
612	Increased Airflow Resistance Because of the Different Materials of the Ventilatory Circuit of Mechanically Ventilated Patients. Clinical Pulmonary Medicine, 1996, 3, 113.	0.3	0

#	Article	IF	CITATIONS
613	Severe Pneumonia: A Step Forward to the Twenty-First Century. Sepsis, 1998, 1, 151-151.	0.5	Ο
614	Diagnosis of ventilator-associated pneumonia. Reviews in Medical Microbiology, 2001, 12, 143-153.	0.9	0
615	Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2006, 4, 321-329.	0.3	0
616	Nosocomial Pneumonia byAcinetobacter baumannii. , 0, , 131-143.		0
617	Atypical Coverage for Community-acquired Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1289-1290.	5.6	0
618	Advances in lower respiratory tract infections in critically ill patients. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2007, 25, 47-57.	0.5	0
619	S286 Treatments for serious Gram-negative infections. International Journal of Antimicrobial Agents, 2007, 29, S58-S59.	2.5	0
620	Costs for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. , 0, , 273-284.		0
621	Prevention of Hospital-Acquired Pneumonia. , 0, , 11-42.		0
622	Hospital-Acquired Pneumonia Caused byStaphylococcus aureus. , 0, , 107-129.		0
623	Acute Respiratory Distress Syndrome and Pneumonia. , 0, , 235-243.		0
624	Oral care practices in critical care unit. Intensive Care Medicine, 2007, 33, 2228-2228.	8.2	0
625	Delayed oxygenation assessment in patients with severe community-acquired pneumonia. Critical Care Medicine, 2008, 36, 1694-1695.	0.9	0
626	Broadening horizons: Research priorities in pneumonia*. Critical Care Medicine, 2010, 38, 1602-1603.	0.9	0
627	Reply to Westley and Chan and to Shih et al Intensive Care Medicine, 2010, 36, 1789-1790.	8.2	0
628	First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain. Medicina Intensiva (English Edition), 2011, 35, 208-216.	0.2	0
629	Return of the flu: leadership, teamwork and foresight. Medicina Intensiva (English Edition), 2011, 35, 460-462.	0.2	0
630	Antibiotic Compliance And Timing In Community-Acquired Pneumonia With Sepsis. , 2011, , .		0

Antibiotic Compliance And Timing In Community-Acquired Pneumonia With Sepsis. , 2011, , . 630

#	Article	IF	CITATIONS
631	The Value of Procalcitonin in CAP Remains Unclear. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1210-1211.	5.6	0
632	Current Key Points in Management for Severe Community-Acquired Pneumonia. Current Respiratory Medicine Reviews, 2011, 7, 250-256.	0.2	0
633	Reply to Petros et al.: Early steriod therapy for patients with H1N1 influenza A virus infection. Intensive Care Medicine, 2011, 37, 1565-1565.	8.2	0
634	New management paradigms for infections in critically ill patients. Current Opinion in Critical Care, 2012, 18, 438-440.	3.2	0
635	Incidence of Respiratory Virus Infection (RVI) in a Prospective Cohort of Lung Transplant Recipien Incidence of Respiratory Virus Infection (RVI) in a Prospective Cohort of Lung Transplant Recipients (LTR). Transplantation, 2012, 94, 950.	1.0	0
636	Role of mannose-binding lectin on pneumococcal infections. Critical Care, 2012, 16, .	5.8	0
637	Intubated patients developing tracheobronchitis or pneumonia have distinctive complement system gene expression signatures in the pre-infection period: A pilot study. Medicina Intensiva (English) Tj ETQq1 1 0.7	784 01 24 rg	3T Øverlock
638	Lung transplant: An emerging challenge in the ICU. Medicina Intensiva (English Edition), 2012, 36, 504-505.	0.2	0
639	PIRO Concept and Clinical Failure. , 2012, , 33-39.		0
640	HipertensiÃ ³ n pulmonar. Revista Espanola De Cardiologia Suplementos, 2013, 13, 1.	0.2	0
641	The impact of lung transplantation on ICU personnel. Medicina Intensiva, 2013, 37, 206-208.	0.7	0
642	Role of biomarkers in the differential diagnosis of acute respiratory failure in the immediate postoperative period of lung transplantation. Medicina Intensiva (English Edition), 2013, 37, 416-422.	0.2	0
643	Differences in hospital- and ventilator-associated pneumonia due to Staphylococcus aureus (methicillin-susceptible and methicillin-resistant) between Europe and Latin America: A comparison of the EUVAP and LATINVAP study cohorts. Medicina Intensiva (English Edition), 2013, 37, 241-247.	0.2	0
644	The impact of lung transplantation on ICU personnel. Medicina Intensiva (English Edition), 2013, 37, 206-208.	0.2	0
645	Acute Respiratory Distress Syndrome and Stem Cells. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 674-675.	5.6	0
646	FLOR Index to Predict the Need of Mechanical Ventilation in Patients With Pneumonia Treated With High Flow Nasal Cannula. Chest, 2014, 145, 180A.	0.8	0
647	Plasma ST2 Predicts Mortality in Patients With Acute Respiratory Distress Syndrome. Chest, 2014, 145, 174A.	0.8	0
648	ICU Readmission of a Lung Transplant Recipient With Acute Respiratory Failure. Chest, 2014, 145, 563A.	0.8	0

0

#	Article	IF	CITATIONS
649	Differences between intraabdominal candidiasis in regular wards versus intensive care unit. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
650	EFFECTS OF DIAPHRAGMATIC PARESIS FOLLOWING LUNG TRANSPLANTATION. Intensive Care Medicine Experimental, 2015, 3, A894.	1.9	0
651	Measles and respiratory failure: Case report and review of the last European outbreaks. Asian Pacific Journal of Tropical Disease, 2015, 5, 669-672.	0.5	0
652	Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus treated with linezolid or vancomycin: A secondary economic analysis of resource use from a Spanish perspective. Medicina Intensiva (English Edition), 2016, 40, 474-482.	0.2	0
653	Risk Factors for Mortality in 272 Patients With Lung Transplant: A Multicenter Analysis of 7 Intensive Care Units. Archivos De Bronconeumologia, 2017, 53, 421-426.	0.8	Ο
654	Response to the Letter to the Editor: Critically ill Haematological Cancer Patients: How far the Severity Index Score can determine the outcome and duration of Aggressive Support?. Australian Critical Care, 2018, 31, 339.	1.3	0
655	Obliterative Bronchiolitis Syndrome and Outcomes of Unplanned ICU Readmission Following Lung Transplantation. Transplantation, 2018, 102, S430-S431.	1.0	Ο
656	Respiratory System Mechanics and Mortality in Immunocompromised ARDS Patients. , 2019, , .		0
657	Ventilator-Associated Events: Definitions and Uses. , 2019, , .		Ο
658	Response. Chest, 2021, 159, 1677-1678.	0.8	0
659	ICU-acquired pneumonia in immunosuppressed patients with acute hypoxemic respiratory failure: A post-hoc analysis of a prospective international cohort study. Journal of Critical Care, 2021, 63, 243-245.	2.2	0
660	Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: the PneumoINSPIRE study. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2021, 23, 59-66.	0.1	0
661	Bullous dermatosis on the hands following SARSâ€CoVâ€2 infection. International Journal of Dermatology, 2021, 60, 1042-1043.	1.0	0
662	New insights in endocarditis caused by Gram negative bacilli not included in the HACEK group. European Journal of Internal Medicine, 2021, 92, 36-37.	2.2	0
663	Hospital-Acquired Pneumonia Caused by Pseudomonas Aeruginosa. Perspectives on Critical Care Infectious Diseases, 2003, , 55-70.	0.1	0
664	Community-Acquired Pneumonia (International Vision). , 2004, , 22-40.		0
665	Microbial etiology and resistance. , 2006, , 613-628.		0

666 Management of Hospital-Associated Pneumonia in the Intensive Care Unit. , 2007, , 449-455.

#	Article	IF	CITATIONS
667	Severe Community-Acquired Pneumonia. , 2007, , 394-403.		0
668	Current Concepts of Severe Pneumococcal Community-acquired Pneumonia. Yearbook of Intensive Care and Emergency Medicine, 2007, , 133-144.	0.1	0
669	Infection of Pulmonary Arterial and Peripheral Arterial Catheters. , 2007, , 324-332.		Ο
670	Mechanical Ventilation for Acute Asthma Exacerbations. Yearbook of Intensive Care and Emergency Medicine, 2008, , 256-268.	0.1	0
671	Mechanical Ventilation for Acute Asthma Exacerbations. , 2008, , 256-268.		0
672	Optimal Antibiotic Use in Severe Community-Acquired Pneumonia. , 2008, , 85-95.		0
673	A PIRO-Based Approach for Severity Assessment in Community-Acquired Pneumonia. , 2009, , 51-63.		0
674	Community-Acquired Pneumonia Management Based on the PIRO System. A New Therapeutic Paradigm. , 2009, , 23-38.		0
675	Drug Distribution: Is it a more Important Determinant of Drug Dosing than Clearance?. , 2010, , 507-516.		0
676	Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review. Current Respiratory Medicine Reviews, 2012, 8, 245-258.	0.2	0
677	Gastroparesis following lung transplantation: Risk factor for pneumonia. , 2015, , .		0
678	Pattern and outcomes of unplanned ICU readmission following lung transplantation. , 2017, , .		0
679	Bringing translational research in acute lung injury closer. Annals of Translational Medicine, 2018, 6, 22-22.	1.7	0
680	An Exceptional Use of Two Gloves Technique During COVID-19 Pandemic. Infectious Diseases and Clinical Microbiology, 2020, 2, 103-105.	0.3	0
681	High-flow nasal cannula oxygen therapy in emergencies: opportunities and containdications. Emergencias, 2018, 30, 380-382.	0.6	0
682	Clinical Approach to the Patient with Hospital-Acquired Pneumonia. , 0, , 79-91.		0
683	Coexisting Purpuric and Pseudo-Chilblain Lesions in COVID-19 Patients Skinmed, 2022, 20, 155-158.	0.0	Ο